Haloperidol Versus Risperidone on Rat "early Onset" Vacuous Chewing
Overview
Psychology
Social Sciences
Authors
Affiliations
Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms. In the present study, the propensities of haloperidol and risperidone in inducing rat "early onset" VCMs were compared using doses of the two antipsychotics that acutely induce similar catalepsy. Comparable rat catalepsy states were observed when the effects produced by 0.1, 0.5, and 1mg/kg of haloperidol were compared with those induced by 1, 4, and 10mg/kg of risperidone, respectively. These doses of the two antipsychotics were then administered twice a day for 4 weeks and VCMs scored after 12h, 5 days, or 3 weeks of drug withdrawal. Among the haloperidol-treated groups, only those rats injected with 0.5 and 1mg/kg showed high levels of VCMs after 12h and 5 days of drug withdrawal when compared to vehicle-treated rats, while basal levels of VCMs were reached after 3 weeks from the last injection. High VCMs levels were observed in risperidone-treated rats only at the dose of 10mg/kg and after 12h of drug withdrawal, but not after 5 days or 3 weeks. The present results indicated that haloperidol possessed a much higher propensity to induce rat "early onset" VCMs than risperidone.
Kajero J, Seedat S, Ohaeri J, Akindele A, Aina O Sci Rep. 2022; 12(1):19718.
PMID: 36385633 PMC: 9669024. DOI: 10.1038/s41598-022-24235-0.
Tsartsalis S, Tournier B, Gloria Y, Millet P, Ginovart N Transl Psychiatry. 2021; 11(1):51.
PMID: 33446643 PMC: 7809418. DOI: 10.1038/s41398-020-01179-5.
Relevance of animal models to human tardive dyskinesia.
Blanchet P, Parent M, Rompre P, Levesque D Behav Brain Funct. 2012; 8:12.
PMID: 22404856 PMC: 3338072. DOI: 10.1186/1744-9081-8-12.
Wolf W, Bieganski G, Guillen V, Mignon L Psychopharmacology (Berl). 2005; 182(1):84-94.
PMID: 15986194 DOI: 10.1007/s00213-005-0033-4.
Betz A, Ishiwari K, Wisniecki A, Huyn N, Salamone J Psychopharmacology (Berl). 2004; 179(2):383-92.
PMID: 15619122 DOI: 10.1007/s00213-004-2046-9.